European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sudhoff Holger
Аннотация
OBJECTIVE: To describe seven cases of patulous Eustachian tube (PET, "Tuba aperta") arising in adult patients undergoing significant weight loss with GLP-1 receptor agonists (semaglutide [Ozempic®] or tirzepatide [Mounjaro®]).
METHODS: Retrospective descriptive case series of patients presenting to our otolaryngology clinic between June 2024 and June 2025 with symptoms of autophony, aural fullness, and audible breathing. All had initiated GLP-1 agonist therapy ≥ 3 months prior and achieved ≥ 8% body-weight reduction. Diagnosis of PET was confirmed by patient symptoms, otoscopy, digital volume tomography, reflex decay tympanometry and tubomanometry.
RESULTS: Seven patients (5 female, 2 male; age 28-56 years) developed bilateral (n = 5) or unilateral (n = 2) PET after 4-10 months of GLP-1 therapy. Weight loss ranged from 8.2 to 18.7% of baseline. Common symptoms were autophony (7/7), intermittent aural fullness (6/7), and hearing one's own breathing (5/7). Conservative management led to symptom improvement in one patient; six required injections of VOX-Implants® into the affected Eustachian tubes with resolution of symptoms.
CONCLUSION: Significant weight loss from GLP-1 receptor agonists may predispose susceptible individuals to PET. Clinicians should be aware of this potential otologic side effect and consider early conservative measures.
METHODS: Retrospective descriptive case series of patients presenting to our otolaryngology clinic between June 2024 and June 2025 with symptoms of autophony, aural fullness, and audible breathing. All had initiated GLP-1 agonist therapy ≥ 3 months prior and achieved ≥ 8% body-weight reduction. Diagnosis of PET was confirmed by patient symptoms, otoscopy, digital volume tomography, reflex decay tympanometry and tubomanometry.
RESULTS: Seven patients (5 female, 2 male; age 28-56 years) developed bilateral (n = 5) or unilateral (n = 2) PET after 4-10 months of GLP-1 therapy. Weight loss ranged from 8.2 to 18.7% of baseline. Common symptoms were autophony (7/7), intermittent aural fullness (6/7), and hearing one's own breathing (5/7). Conservative management led to symptom improvement in one patient; six required injections of VOX-Implants® into the affected Eustachian tubes with resolution of symptoms.
CONCLUSION: Significant weight loss from GLP-1 receptor agonists may predispose susceptible individuals to PET. Clinicians should be aware of this potential otologic side effect and consider early conservative measures.